List view / Grid view
22 April 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit...
22 April 2015 | By Victoria White
Nimbus Therapeutics has initiated a Phase I clinical programme for NDI-010976 for the treatment of NASH and related fatty liver disease-spectrum disorders...
22 April 2015 | By Victoria White
Pfizer’s XALKORI has received Breakthrough Therapy designation from the FDA for the potential treatment of patients with ROS1-positive NSCLC...
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
22 April 2015 | By Victoria White
GW Pharmaceuticals has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare form of childhood epilepsy...
21 April 2015 | By Victoria White
Pfizer Phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)...
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
21 April 2015 | By Cobalt Light Systems
Cobalt Light Systems has been named as a recipient of the prestigious 2015 Queen’s Award for Enterprise...
21 April 2015 | By kdm communications
A Syrris Atlas Calorimeter is proving advantageous to the Kyushu works manufacturing technology department of Nippon Steel & Sumikin Chemical Co., Ltd. in Japan, aiding scale-up of new product processes...
21 April 2015 | By Victoria White
TetraLogic and Merck are to collaborate to evaluate a combination of birinapant and KEYTRUDA in patients with relapsed or refractory solid tumours...
21 April 2015 | By Victoria White
ARIAD has announced updated clinical data on its tyrosine kinase inhibitor, brigatinib, in patients with ALK+ NSCLC from an ongoing Phase 1/2 trial...
21 April 2015 | By Victoria White
Results of the double-blind placebo-controlled Phase III trial demonstrating efficacy and safety of Raxone/Catena in patients with DMD have been published...
21 April 2015 | By Victoria White
ReNeuron has provided a further and final update on the PISCES Phase I clinical trial of its CTX stem cell therapy for disabled stroke patients...
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
20 April 2015 | By Victoria White
Results from the randomised, pivotal Phase 3 study of KEYTRUDA versus ipilimumab in the treatment of unresectable advanced melanoma have been announced...
